Page last updated: 2024-11-08

biphenylylacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

biphenylylacetic acid: metabolite of BHD 7538; RN given refers to cpd with unspecified locants for acetic acid moities [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156614087
MeSH IDM0060044

Synonyms (3)

Synonym
(1,1'-biphenyl)acetic acid
acetic acid, biphenylyl-
biphenylylacetic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"(S)-10-[(S)-(8-Amino-6-azaspiro[3,4]octan-6-yl)]-9-fluoro-2, 3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxyli c acid hemihydrate (CAS 151390-79-3, DV-7751a) a new quinolone antibacterial agent, was examined for LD50 value, phototoxicity and convulsion inducing potential in laboratory animals."( LD50 value, phototoxicity and convulsion induction test of the new quinolone antibacterial agent (S)-10-[(S)-(8-amino-6-azaspiro[3,4]octan-6-yl)]-9-fluoro-2, 3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxyl ic acid hemihydrate in la
Akahane, K; Kato, M; Nomura, M; Shimoda, K, 1996
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
"In order to clarify the possibility of pharmacokinetic interaction between quinolone and fenbufen, the plasma concentration-time profiles and serum protein binding of enoxacin, fenbufen and its active metabolite, felbinac, were investigated in rats."( A minor possibility of pharmacokinetic interaction between enoxacin and fenbufen in rats.
Hayashibara, M; Ichikawa, N; Iwamoto, K; Katagiri, Y; Naora, K, 1990
)
0.28
"The possible pharmacokinetic interaction between a new quinolone and fenbufen was investigated by comparing the plasma concentration-time profiles and serum protein binding of ofloxacin, fenbufen and its active metabolite, felbinac, in rats."( Absence of pharmacokinetic interaction between ofloxacin and fenbufen in rats.
Hayashibara, M; Ichikawa, N; Iwamoto, K; Katagiri, Y; Naora, K, 1989
)
0.28
" The method was applied to a preclinical pharmacokinetic study in rat involving a single intravenous injection of felbinac trometamol."( Validated LC-MS/MS assay for the determination of felbinac: Application to a preclinical pharmacokinetics study of felbinac trometamol injection in rat.
Fawcett, JP; Gu, J; Sun, Y; Wang, L; Wang, X; Yang, W; Zhang, C, 2009
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effects of enoxacin, a new quinolone antibacterial agent, and its combination with 4-biphenylacetate (BPA), an active metabolite of the non-steroidal antiinflammatory agent fenbufen, were examined on population spikes induced by electrical stimulation of the stratum radiatum in the CA1 pyramidal cell layer in rat hippocampal slices."( Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices.
Hori, S; Ito, T; Kadokawa, T; Miura, Y; Miyahara, T; Shimada, J, 1991
)
0.28

Bioavailability

ExcerptReferenceRelevance
" The pharmacokinetic profiles of BPAA-beta-CyD complexes have shown that DM-beta-CyD is the most effective in enhancing the bioavailability of BPAA."( Differential effects of modified beta-cyclodextrins on pharmacological activity and bioavailability of 4-biphenylacetic acid in rats after oral administration.
Campana, G; Puglisi, G; Spadaro, A; Spampinato, S; Ventura, CA, 1995
)
0.29
" Compounds demonstrated potency in a human DP2 binding assay and a human whole blood eosinophil shape change assay, as well as good oral bioavailability in rat and dog, and efficacy in a mouse model of allergic rhinitis following oral dosing."( Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.
Baccei, C; Bain, G; Broadhead, A; Evans, JF; Fagan, P; Hutchinson, JH; King, C; Lee, C; Lorrain, DS; Prasit, P; Prodanovich, P; Santini, A; Scott, JM; Stearns, BA, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" The dose-response relationships showed that the effect of enoxacin was 100 times potentiated in the presence of BPA (10(-5) M)."( Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices.
Hori, S; Ito, T; Kadokawa, T; Miura, Y; Miyahara, T; Shimada, J, 1991
)
0.28
" In addition, the mock patches were formulated with typical ester ingredients for transdermal dosage forms."( [Pharmaceutical Properties of Anti-inflammatory Analgesic Patches Using Acrylic Polymer].
Fukami, T; Gato, K; Kato, S; Koide, T; Shikaku, R; Yoshimura-Fujii, M, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (90)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (20.00)18.7374
1990's37 (41.11)18.2507
2000's15 (16.67)29.6817
2010's18 (20.00)24.3611
2020's2 (2.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (9.47%)5.53%
Reviews4 (4.21%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other82 (86.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Placebo-controlled, Single-dose, Multiple-dose,Dose-escalated Phase I Clinical Study Trial to Evaluate the Tolerance and Pharmacokinetics of Felbinac Trometamol Injection in Healthy Subjects [NCT03617510]Phase 148 participants (Actual)Interventional2018-07-10Completed
A Phase I Study to the Safety, Tolerability, and Pharmacokinetic Characteristics of Felbinac Trometamol Eye Drops of Single-dose and Multiple-dose in Healthy Subjects [NCT05085106]Phase 148 participants (Anticipated)Interventional2020-10-21Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-exploratory Phase II Clinical Trial to Evaluating the Efficacy and Safety of Felbinac Trometamol Injection in the Treatment of Moderate to Severe Pain After Surgery [NCT03872830]Phase 2165 participants (Actual)Interventional2019-03-27Completed
A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase Ⅲ Clinical Trial on the Efficacy and Safety of Felbinac Trometamol Injection in the Treatment of Moderate and Severe Postoperative Pain [NCT04526132]Phase 3306 participants (Actual)Interventional2021-04-25Completed
A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalated Phase I Clinical Study Trial to Evaluate the Tolerance and Pharmacokinetics of Felbinac Trometamol Injection in Healthy Subjects [NCT03235778]Phase 158 participants (Actual)Interventional2017-07-17Completed
A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase Ⅲ Clinical Trial on the Efficacy and Safety of Felbinac Trometamol Injection in the Treatment of Postoperative Pain in Gynecology [NCT05297669]Phase 3264 participants (Actual)Interventional2021-07-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]